J&J files suit against Amgen to protect Procrit sales

Share this article:
Johnson & Johnson has filed an antitrust lawsuit accusing rival Amgen of engaging in illegal sales practices to drive its best-selling drug Procrit (epoetin alfa) out of the market.
The lawsuit was filed in Federal District Court in Trenton, N.J.
"We believe the allegations in the complaint are without merit, and we plan to vigorously defend our position," Mary Klem, Amgen associate director, external communications, told MM&M.
The dispute involves Amgen's anti-anemia drug, Aranesp (darbepoetin alfa), which J&J's Ortho Biotech said now accounts for about two-thirds of sales to oncology clinics for products to aid red-blood cell growth.
Ortho Biotech claimed in the suit that Amgen penalizes oncology clinics by requiring they buy nearly all red blood-cell growth drugs from Amgen if the clinics want good deals on its two white blood-cell growth drugs, Neulasta (pegfilgrastim) and Neupogen (filgrastim).
Amgen has a near monopoly for the lifesaving white blood cell drugs, with 98 percent of clinic sales, Ortho Biotech said.
Failure to buy at least 75 percent of red blood cell growth drugs from Amgen means that a clinic will have to buy Neulasta and Neupogen at prices that exceed government reimbursement, the lawsuit said.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.